These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate. Lindahl K; Kindmark A; Rubin CJ; Malmgren B; Grigelioniene G; Söderhäll S; Ljunggren Ö; Åström E Bone; 2016 Jun; 87():11-8. PubMed ID: 26957348 [TBL] [Abstract][Full Text] [Related]
3. Reduced spinal bone mineral density in adolescents of an Ultra-Orthodox Jewish community in Brooklyn. Taha W; Chin D; Silverberg AI; Lashiker L; Khateeb N; Anhalt H Pediatrics; 2001 May; 107(5):E79. PubMed ID: 11331729 [TBL] [Abstract][Full Text] [Related]
4. Bone structure assessed by HR-pQCT, TBS and DXL in adult patients with different types of osteogenesis imperfecta. Kocijan R; Muschitz C; Haschka J; Hans D; Nia A; Geroldinger A; Ardelt M; Wakolbinger R; Resch H Osteoporos Int; 2015 Oct; 26(10):2431-40. PubMed ID: 25956285 [TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up in osteogenesis imperfecta type VI. Trejo P; Palomo T; Montpetit K; Fassier F; Sato A; Glorieux FH; Rauch F Osteoporos Int; 2017 Oct; 28(10):2975-2983. PubMed ID: 28689307 [TBL] [Abstract][Full Text] [Related]
6. Lumbar spine bone mineral density Z-score discrepancies by dual X-ray absorptiometry do not predict vertebral fractures in children. Harindhanavudhi T; Petryk A; Jones R; Regodón Wallin A; Hodges JS; Nortwick SV; Miller BS; Holm TL; Sarafoglou K J Investig Med; 2018 Aug; 66(6):980-985. PubMed ID: 29622758 [TBL] [Abstract][Full Text] [Related]
7. Changes in trabecular bone density in incident pediatric Crohn's disease: a comparison of imaging methods. Tsampalieros A; Berkenstock MK; Zemel BS; Griffin L; Shults J; Burnham JM; Baldassano RN; Leonard MB Osteoporos Int; 2014 Jul; 25(7):1875-83. PubMed ID: 24760243 [TBL] [Abstract][Full Text] [Related]
8. Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists. Bradbury LA; Barlow S; Geoghegan F; Hannon RA; Stuckey SL; Wass JA; Russell RG; Brown MA; Duncan EL Osteoporos Int; 2012 Jan; 23(1):285-94. PubMed ID: 21739105 [TBL] [Abstract][Full Text] [Related]
9. High and low density in the same bone: a study on children and adolescents with mild osteogenesis imperfecta. Rauch F; Land C; Cornibert S; Schoenau E; Glorieux FH Bone; 2005 Nov; 37(5):634-41. PubMed ID: 16112635 [TBL] [Abstract][Full Text] [Related]
10. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. Letocha AD; Cintas HL; Troendle JF; Reynolds JC; Cann CE; Chernoff EJ; Hill SC; Gerber LH; Marini JC J Bone Miner Res; 2005 Jun; 20(6):977-86. PubMed ID: 15883638 [TBL] [Abstract][Full Text] [Related]
11. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment. Land C; Rauch F; Travers R; Glorieux FH Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117 [TBL] [Abstract][Full Text] [Related]
12. Correlation of scoliotic curvature with Z-score bone mineral density and body mass index in patients with osteogenesis imperfecta. Watanabe G; Kawaguchi S; Matsuyama T; Yamashita T Spine (Phila Pa 1976); 2007 Aug; 32(17):E488-94. PubMed ID: 17762282 [TBL] [Abstract][Full Text] [Related]
13. Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years. Palomo T; Fassier F; Ouellet J; Sato A; Montpetit K; Glorieux FH; Rauch F J Bone Miner Res; 2015 Dec; 30(12):2150-7. PubMed ID: 26059976 [TBL] [Abstract][Full Text] [Related]
14. Risk factors for low bone mineral density in pediatric inflammatory bowel disease: the positive role of physical activity. Nobile S; Grand RJ; Pappa HM Eur J Gastroenterol Hepatol; 2018 Apr; 30(4):471-476. PubMed ID: 29438136 [TBL] [Abstract][Full Text] [Related]
15. Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment. Land C; Rauch F; Munns CF; Sahebjam S; Glorieux FH Bone; 2006 Oct; 39(4):901-6. PubMed ID: 16730480 [TBL] [Abstract][Full Text] [Related]
16. Diagnosis of Recurrent Fracture in a Pediatric Cohort. Fiscaletti M; Coorey CP; Biggin A; Briody J; Little DG; Schindeler A; Munns CF Calcif Tissue Int; 2018 Nov; 103(5):529-539. PubMed ID: 29943187 [TBL] [Abstract][Full Text] [Related]
17. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Zeitlin L; Rauch F; Plotkin H; Glorieux FH Pediatrics; 2003 May; 111(5 Pt 1):1030-6. PubMed ID: 12728084 [TBL] [Abstract][Full Text] [Related]
18. Individualized evaluation of lumbar bone mineral density in children with cerebral palsy. Duran I; Katzmann J; Martakis K; Stark C; Semler O; Schoenau E Arch Osteoporos; 2018 Nov; 13(1):120. PubMed ID: 30397843 [TBL] [Abstract][Full Text] [Related]
19. Vertebral bone mass, size, and volumetric density in women with spinal fractures. Duan Y; Parfitt Am; Seeman E J Bone Miner Res; 1999 Oct; 14(10):1796-802. PubMed ID: 10491228 [TBL] [Abstract][Full Text] [Related]
20. Bone mineral density of the lumbar spine of Brazilian children and adolescents aged 6 to 14 years. Fonseca AS; Szejnfeld VL; Terreri MT; Goldenberg J; Ferraz MB; Hilário MO Braz J Med Biol Res; 2001 Mar; 34(3):347-52. PubMed ID: 11262585 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]